Novo Nordisk A/ S stock (DK0060534915): Weight-loss and diabetes leader faces pricing and competition pressures

Novo Nordisk A/S shares have been under pressure as investors weigh pricing scrutiny, competition in obesity drugs, and valuation concerns.

Novo Nordisk A/S stock has come under pressure in recent months as investors reassess the long-term growth outlook for the Danish pharmaceutical giant, which dominates the global market for GLP-1 drugs used to treat obesity and type 2 diabetes. Shares of the Copenhagen-listed company have pulled back from record highs reached in 2024 and 2025, reflecting concerns about pricing pressure, regulatory scrutiny, and the emergence of rival products from Eli Lilly and other biotech firms. The pullback has turned a previously one-way trade into a more nuanced debate about valuation, pipeline durability, and the sustainability of rapid sales growth for drugs such as Wegovy and Ozempic.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk A/S
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: Denmark
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: GLP-1 drugs (Wegovy, Ozempic), insulin products, diabetes care devices
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NOVO B)
• Trading currency: Danish krone (DKK)

Novo Nordisk A/S: core business model

Novo Nordisk A/S is a global leader in diabetes care and obesity treatment, with a business model built around proprietary injectable therapies and related devices. The company’s core franchise centers on glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic a hormone that regulates blood sugar and appetite. These drugs have become central to the treatment of type 2 diabetes and, more recently, chronic weight management in adults with obesity or overweight and related comorbidities. Novo Nordisk’s commercial success has been driven by a combination of strong clinical data, broad label expansions, and an extensive global sales and distribution network.

The company operates through two main business areas: Diabetes Care and Obesity Care. Within Diabetes Care, Novo Nordisk markets a portfolio of insulins and GLP-1–based products, including long-acting basal insulins and once-weekly GLP-1 agonists such as Ozempic. The Obesity Care segment is anchored by Wegovy, a higher-dose GLP-1 formulation approved for chronic weight management. Both segments benefit from recurring prescription demand, relatively high patient retention, and long product lifecycles supported by ongoing clinical development and label extensions.

Novo Nordisk’s strategy emphasizes innovation, lifecycle management, and geographic expansion. The company invests heavily in research and development to extend the indications for existing drugs, improve dosing regimens, and develop next-generation molecules. It also continues to expand manufacturing capacity to meet surging global demand, particularly in the United States, where obesity and diabetes prevalence remain high and payer coverage for GLP-1 therapies has expanded over time.

Main revenue and product drivers for Novo Nordisk A/S

Novo Nordisk’s revenue growth in recent years has been dominated by its GLP-1 franchise, with Wegovy and Ozempic serving as the primary growth engines. Wegovy, approved for chronic weight management, has seen rapid uptake in the United States and other major markets, driven by strong efficacy data and growing awareness among physicians and patients. Ozempic, originally developed for type 2 diabetes, has also been prescribed off-label for weight loss, further amplifying demand and contributing to supply constraints that have persisted into 2026.

Insulin products remain a significant revenue contributor, particularly in markets where GLP-1 therapies are less accessible due to cost or reimbursement constraints. Novo Nordisk’s insulin portfolio includes basal, prandial, and premixed formulations that cater to a broad spectrum of diabetes patients. The company has also introduced combination products that pair GLP-1 agonists with insulin, aiming to simplify treatment regimens and improve adherence. These combination therapies are expected to gain traction as payers and providers seek more integrated solutions for complex diabetes management.

Looking ahead, Novo Nordisk is advancing a pipeline of next-generation obesity and diabetes drugs, including oral GLP-1 formulations and dual- or triple-agonist molecules that target multiple metabolic pathways. The company is also exploring applications beyond obesity and diabetes, such as nonalcoholic steatohepatitis (NASH) and cardiovascular risk reduction, which could broaden the addressable market for its GLP-1 platform. However, the timing and commercial success of these pipeline assets remain uncertain, and investors are closely watching clinical readouts and regulatory decisions over the next few years.

Conclusion

Novo Nordisk A/S remains a central player in the global obesity and diabetes markets, with a powerful GLP-1 franchise and a deep pipeline of metabolic therapies. The company’s shares have benefited from years of robust sales growth and expanding indications, but recent price action reflects growing concerns about competition, pricing pressure, and the sustainability of current growth rates. For US investors, the stock offers exposure to a secular trend in obesity treatment and metabolic disease management, but also carries risks related to regulatory developments, payer pushback, and the pace of innovation from rivals.

Investors considering Novo Nordisk A/S should weigh the company’s strong brand recognition, global scale, and recurring revenue base against the potential for margin compression, increased competition, and pipeline execution risk. The stock may appeal to long-term investors seeking exposure to the obesity and diabetes space, but those sensitive to valuation or regulatory uncertainty may prefer to wait for clearer signals on pricing dynamics and the competitive landscape. As with any equity investment, diversification and a clear understanding of risk tolerance are important when evaluating a position in Novo Nordisk A/S.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.